Agoraphobia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: AGR002 MIFTS: 46	Agoraphobia Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia ¹² ⁷⁶ ⁵⁵ ⁴⁴ ¹⁵ ⁷³

Fear of Open Spaces ¹²

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Mental and behavioural disorders

Neurotic, stress-related and somatoform disorders

Phobic anxiety disorders

Agoraphobia

External Ids:

Disease Ontology ¹² DOID:593

ICD10 ³³ F40.0 F40.00

MeSH ⁴⁴ D000379

NCIt ⁵⁰ C34362

SNOMED-CT ⁶⁸ 154885006 192394003 247830007 more

UMLS ⁷³ C0001818

Sources

Summaries for Agoraphobia

Disease Ontology : ¹² A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to depression and social phobia. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Sertraline and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include colon, brain and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : ⁷⁶ Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Sources

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)

#	Related Disease	Score	Top Affiliating Genes
1	depression	31.0	HTR1A MAOA SLC6A4
2	social phobia	30.9	HTR1A MAOA SLC6A4
3	personality disorder	30.8	HTR1A MAOA SLC6A4
4	obsessive-compulsive disorder	30.6	HTR1A MAOA SLC6A4
5	major depressive disorder	29.0	HTR1A MAOA SLC6A2 SLC6A4
6	generalized anxiety disorder	28.9	HTR1A MAOA RGS2 SLC6A2 SLC6A4
7	anxiety	28.8	CCKBR HTR1A MAOA PTK7 SLC6A2 SLC6A4
8	panic disorder	28.5	CCKBR HTR1A MAOA PTK7 RGS2 SLC6A2
9	alcohol dependence	28.5	HTR1A MAOA OPRK1 SLC6A4
10	panic disorder 1	11.2
11	psychosexual disorder	10.7	HTR1A SLC6A4
12	premature ejaculation	10.7	HTR1A SLC6A4
13	periodic limb movement disorder	10.6	HTR1A SLC6A4
14	alexithymia	10.6	HTR1A SLC6A4
15	intermittent explosive disorder	10.6	HTR1A SLC6A4
16	atypical depressive disorder	10.6	MAOA SLC6A4
17	pathological gambling	10.5	MAOA SLC6A4
18	migraine without aura	10.5	HTR1A SLC6A4
19	antisocial personality disorder	10.5	MAOA SLC6A4
20	paranoid schizophrenia	10.5	MAOA SLC6A4
21	early-onset schizophrenia	10.5	MAOA SLC6A4
22	bipolar i disorder	10.4	HTR1A SLC6A4
23	endogenous depression	10.4	MAOA SLC6A4
24	dyspepsia	10.4	HTR1A SLC6A4
25	kleptomania	10.3	HTR1A MAOA SLC6A4
26	obsessive-compulsive personality disorder	10.3	PIR SLC6A4
27	brunner syndrome	10.3	HTR1A MAOA SLC6A4
28	schizoid personality disorder	10.3	HTR1A PIR
29	postpartum depression	10.3	HTR1A MAOA SLC6A4
30	borderline personality disorder	10.3	HTR1A MAOA SLC6A4
31	serotonin syndrome	10.3	HTR1A MAOA SLC6A4
32	chronic fatigue syndrome	10.3	HTR1A MAOA SLC6A4
33	migraine with or without aura 1	10.2	HTR1A MAOA SLC6A4
34	cocaine abuse	10.2	SLC6A2 SLC6A4
35	sudden infant death syndrome	10.2	HTR1A MAOA SLC6A4
36	conduct disorder	10.2	MAOA SLC6A4
37	oppositional defiant disorder	10.0	MAOA SLC6A2 SLC6A4
38	bulimia nervosa	10.0	MAOA SLC6A4
39	eating disorder	10.0
40	dysthymic disorder	9.9	MAOA PIR SLC6A4
41	aging	9.9
42	separation anxiety disorder	9.9
43	thyroiditis	9.9
44	opiate dependence	9.9	OPRK1 SLC6A4
45	autism	9.8	GRPR HTR1A MAOA SLC6A4
46	hypochondriasis	9.8
47	melancholia	9.8
48	irritable bowel syndrome	9.8
49	substance abuse	9.8	MAOA SLC6A4
50	opioid addiction	9.8	CCKBR OPRK1

Graphical network of the top 20 diseases related to Agoraphobia:

Sources

Symptoms & Phenotypes for Agoraphobia

MGI Mouse Phenotypes related to Agoraphobia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.86	SLC6A4 CCKBR GRPR HTR1A MAOA OPRK1
2	cardiovascular system	MP:0005385	9.76	SLC6A4 CCKBR STMN1 HTR1A MAOA PTK7
3	homeostasis/metabolism	MP:0005376	9.56	SLC6A4 CCKBR STMN1 GRPR HTR1A MAOA
4	nervous system	MP:0003631	9.28	SLC6A4 CCKBR STMN1 HTR1A MAOA OPRK1

Sources

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sertraline

Approved

Phase 4

79617-96-2

68617

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Alprazolam

Approved, Illicit, Investigational

Phase 4,Phase 1

28981-97-7

2118

Clonazepam

Approved, Illicit

Phase 4

1622-61-3

2802

Paroxetine

Approved, Investigational

Phase 4,Phase 3

61869-08-7

43815

Central Nervous System Depressants

Phase 4,Phase 1

Central Nervous System Stimulants

Phase 4

GABA Agents

Phase 4,Phase 1

GABA Modulators

Phase 4,Phase 1

Serotonin Agents

Phase 4,Phase 3

Serotonin Uptake Inhibitors

Phase 4,Phase 3

Neurotransmitter Agents

Phase 4,Phase 3,Phase 1,Not Applicable

Neurotransmitter Uptake Inhibitors

Phase 4,Phase 3

Cytochrome P-450 CYP2D6 Inhibitors

Phase 4,Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 3

Tranquilizing Agents

Phase 4,Phase 1

Anti-Anxiety Agents

Phase 4,Phase 1,Not Applicable

Dopamine Agents

Phase 4

Dopamine Uptake Inhibitors

Phase 4

Hypnotics and Sedatives

Phase 4,Phase 1

Anticonvulsants

Phase 4

Antidepressive Agents

Phase 4,Phase 3,Not Applicable

Antidepressive Agents, Second-Generation

Phase 4,Phase 3

Lisdexamfetamine Dimesylate

Phase 4

Psychotropic Drugs

Phase 4,Phase 3,Phase 1

Rho(D) Immune Globulin

Phase 4

gamma-Globulins

Phase 4

Antibodies

Phase 4

Immunoglobulins

Phase 4

Immunoglobulins, Intravenous

Phase 4

Serotonin

Investigational, Nutraceutical

Phase 4,Phase 3

50-67-9

5202

Cycloserine

Approved

Phase 2

68-41-7

401 6234

Renal Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Anti-Infective Agents

Phase 2

Antitubercular Agents

Phase 2

Antimetabolites

Phase 2

Citalopram

Approved

59729-33-8

2771

Adenosine

Approved, Investigational

58-61-7

60961

Propranolol

Approved, Investigational

Not Applicable

525-66-6

4946

Magnesium Sulfate

Approved, Investigational, Vet_approved

Not Applicable

7487-88-9

24083

Caffeine

Approved, Nutraceutical

58-08-2

2519

Pharmaceutical Solutions

Not Applicable

Analgesics

Cholinergic Agents

Muscarinic Antagonists

Cholinergic Antagonists

Parasympatholytics

Anti-Arrhythmia Agents

,Not Applicable

Interventional clinical trials:

(show top 50) (show all 84)

#	Name	Status	NCT ID	Phase	Drugs
1	Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine	Completed	NCT02852577	Phase 4	Clonazepam;Paroxetine
2	A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder	Completed	NCT00677352	Phase 4	sertraline;Paroxetine
3	Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder	Completed	NCT00540098	Phase 4	paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
4	Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity	Completed	NCT01863459	Phase 4	Lisdexamfetamine Dimesylate;placebo
5	Treatments for Anxiety: Meditation and Escitalopram	Recruiting	NCT03522844	Phase 4	Escitalopram
6	A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)	Active, not recruiting	NCT03348618	Phase 4
7	A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks	Terminated	NCT00634790	Phase 4	alprazolam XR
8	Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders	Terminated	NCT00182533	Phase 4	Sertraline;Placebo
9	Mechanisms of Panic Disorders Treatment	Unknown status	NCT01323556	Phase 2, Phase 3
10	Virtual Reality Exposure Therapy in Agoraphobic Participants	Completed	NCT00734370	Phase 2, Phase 3
11	Treatment of Panic Disorder: Long Term Strategies	Completed	NCT00000368	Phase 3	Paroxetine or other medication - algorithm used
12	Comparison of Psychotherapy Programs to Treat Panic Disorder	Completed	NCT00353470	Phase 3
13	Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder	Completed	NCT00845260	Phase 3
14	Treatment of Social Phobia and Panic Disorder in Adults	Completed	NCT00619138	Phase 3
15	Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria	Completed	NCT00785135	Phase 3
16	Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study	Not yet recruiting	NCT03549819	Phase 3	Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
17	Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia	Completed	NCT01928823	Phase 2	D-Cycloserine
18	Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia	Completed	NCT00576719	Phase 2
19	Exposure Therapy for Fear of Falling in Older Adults	Completed	NCT01609322	Phase 2
20	Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial	Completed	NCT01076777	Phase 2
21	Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder	Completed	NCT00705380	Phase 2
22	Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia	Recruiting	NCT01680237	Phase 2
23	Improve: Integrating Emotion Focused Components Into Psychological Therapy	Recruiting	NCT02822443	Phase 2
24	The Modular Protocol for Mental Health (MPMH)	Enrolling by invitation	NCT03143634	Phase 1, Phase 2
25	An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites	Completed	NCT01330472	Phase 1	Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
26	Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia	Unknown status	NCT00129610	Not Applicable
27	Virtual Reality and Concept of Control in the Treatment of Acrophobia	Unknown status	NCT02020824	Not Applicable
28	Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway	Unknown status	NCT02150265	Not Applicable
29	Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma	Unknown status	NCT02030522	Not Applicable
30	Thought Field Therapy and Cognitive Therapy for Agoraphobia	Completed	NCT00932919	Not Applicable
31	Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia	Completed	NCT01928810	Not Applicable
32	Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia	Completed	NCT01446172
33	Mechanisms of Treatment Change in Panic Disorder and Agoraphobia	Completed	NCT03547180	Not Applicable
34	Cognitive Behavioral Therapy in Panic Disorder	Completed	NCT00772746
35	Internet-based Exposure Therapy for Panic Disorder	Completed	NCT03061448	Not Applicable
36	Physical Activity and Cognitive Behavioural Therapy in Panic Disorder	Completed	NCT01788800	Not Applicable
37	Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia	Completed	NCT00004367	Not Applicable
38	Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?	Completed	NCT00202709	Not Applicable
39	Cognitive Behavior Psychotherapy in Panic Disorder	Completed	NCT01025908	Not Applicable
40	Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction	Completed	NCT00004366	Not Applicable
41	Interpretation Modification Program for Social Phobia	Completed	NCT00684541	Not Applicable
42	Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	Completed	NCT00711737
43	Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome	Completed	NCT02833194
44	Genetic Causes of Panic Disorder	Completed	NCT00083265
45	Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU)	Completed	NCT01207674	Not Applicable
46	A Randomized Controlled Trial of PCIT-ED for Preschool Depression	Completed	NCT02076425	Not Applicable
47	RCT of Bibliotherapy for Social Anxiety Disorder as a Prelude to CBT in IAPT	Completed	NCT02307097	Not Applicable
48	Youth Mayo Clinic Anxiety Coach Pilot Study	Completed	NCT02205177	Not Applicable
49	Internet-Delivered Cognitive Behavior Therapy for Anxiety and Depression Amongst French Canadians	Completed	NCT03043833	Not Applicable
50	Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD	Completed	NCT01682447	Not Applicable

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

alprazolam

Cochrane evidence based reviews: agoraphobia

Sources

Genetic Tests for Agoraphobia

Sources

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

⁴¹

Colon, Brain, Cortex, Thyroid, Pituitary, Amygdala, Breast

Sources

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 565)

#	Title	Authors	Year
1	Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. ( 29899808 )	Palardy V....Guay S.	2018
2	The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament. ( 29649673 )	BeA9irli A.	2018
3	Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. ( 29391399 )	Wichmann S....Petrowski K.	2018
4	Bowel and Bladder Anxiety: An Obsession or a Variant of Agoraphobia? ( 29875534 )	Roy D....Prithviraj M.	2018
5	Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. ( 29539585 )	Bischoff S....StrAPhle A.	2018
6	Pretreatment Cardiac Vagal Tone Predicts Dropout from and Residual Symptoms after Exposure Therapy in Patients with Panic Disorder and Agoraphobia. ( 29533952 )	Wendt J....Richter J.	2018
7	Fear of Fear and Broad Dimensions of Psychopathology over the Course of Cognitive Behavioural Therapy for Panic Disorder with Agoraphobia in Japan. ( 29259145 )	Ogawa S....Akechi T.	2017
8	Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )	Ikic V....Marchand A.	2017
9	Thought Field Therapy Compared to Cognitive Behavioral Therapy and Wait-List for Agoraphobia: A Randomized, Controlled Study with a 12-Month Follow-up. ( 28676782 )	Irgens A.C....NysA	2017
10	No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )	Hofmeijer-Sevink M.K....Cath D.C.	2017
11	Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )	Masdrakis V.G....Markianos M.	2017
12	Two Novel Cognitive Behavioral Therapy-Based Mobile Apps for Agoraphobia: Randomized Controlled Trial. ( 29175809 )	Christoforou M....Tsakanikos E.	2017
13	Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )	Borgo E.L....Torres A.R.	2017
14	Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. ( 28845177 )	Heo J.Y....Lee J.E.	2017
15	Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )	Sundermann B....Pfleiderer B.	2017
16	Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. ( 29085773 )	Deppermann S....Zwanzger P.	2017
17	Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )	Batinic B....Baldwin D.S.	2017
18	Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )	Arnfred S.M....Reinholt N.	2017
19	PanelA Report, IPA Congress Buenos Aires 2017: Claustro-agoraphobia, Bertram Lewin, and the oral triad 6 April 2017. ( 29148571 )	Ithier B.	2017
20	The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. ( 27449053 )	Hoffart A....Johnson S.U.	2016
21	Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report. ( 27828703 )	Ray S.M....Kious B.M.	2016
22	Facing the fear - clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. ( 26837851 )	Liebscher C....StrAPhle A.	2016
23	Agoraphobia Related to Unassertiveness in Panic Disorder. ( 26915016 )	Levitan M.N....Nardi A.E.	2016
24	A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. ( 27594602 )	Benecke C....Schauenburg H.	2016
25	Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. ( 27071857 )	Pompoli A....Salanti G.	2016
26	Cognitive Models for Panic Disorder With Agoraphobia: A Study of Disaggregated Within-Person Effects. ( 27123977 )	Hoffart A.	2016
27	Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. ( 26588081 )	Hoffart A....Sexton H.	2016
28	A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. ( 27423353 )	Inoue K....Okazaki Y.	2016
29	Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. ( 26877119 )	Hamm A.O....Deckert J.	2016
30	Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. ( 27730622 )	Imai H....Furukawa T.A.	2016
31	Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia. ( 27725796 )	Gallagher S....Trigg D.	2016
32	Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). ( 27450798 )	Ghazal Y.A....Hinton D.E.	2016
33	SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( 26663632 )	Payne L.A....Barlow D.H.	2016
34	Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. ( 27061246 )	Duits P....Cath D.C.	2016
35	Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. ( 27385412 )	BAclanger C....Perreault M.	2016
36	Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )	Cousineau H....Belleville G.	2016
37	The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 27235836 )	Weck F....Lang T.	2016
38	Association of human microRNAs miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. ( 26361067 )	Kim B....Lee S.H.	2015
39	Evidence for chronic low-grade systemic inflammation in individuals with agoraphobia from a population-based prospective study. ( 25875094 )	Wagner E.Y....von KAonel R.	2015
40	Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. ( 25722042 )	Gloster A.T....Wittchen H.U.	2015
41	A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. ( 26443228 )	Porter E....Chambless D.L.	2015
42	An admixture analysis of age of onset in agoraphobia. ( 25898330 )	Tibi L....Anholt G.E.	2015
43	Intensive behavioral therapy for agoraphobia. ( 25479049 )	Knuts I.J....Schruers K.R.	2015
44	The combined use of virtual reality exposure in the treatment of agoraphobia. ( 26150057 )	Pitti C.T....Gracia R.	2015
45	Panic disorder and agoraphobia: A direct comparison of their multivariate comorbidity patterns. ( 26480214 )	Greene A.L....Eaton N.R.	2015
46	Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach. ( 26308791 )	Klan T....Hiller W.	2015
47	Frontal cortex absolute beta power measurement in Panic Disorder with Agoraphobia patients. ( 26093831 )	De Carvalho M.R....Ribeiro P.	2015
48	Agoraphobia and Melancholia: Thoughts on Milrod's &quot;Emptiness in Agoraphobia Patients&quot;. ( 26263925 )	Yates S.	2015
49	CLINICAL CONSEQUENCES OF THE REVISED DSM-5 DEFINITION OF AGORAPHOBIA IN TREATMENT-SEEKING ANXIOUS YOUTH. ( 25845579 )	Cornacchio D....Comer J.	2015
50	Social Anxiety Disorder and Agoraphobia in Dermatology Patients; Two Cases and a Review of the Literature. ( 25721467 )	Marshall C....Bewley A.	2015

Sources

Genes for Agoraphobia

Genes related to Agoraphobia (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	24.77	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10870873 14984628
2	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	23.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	MAOA	Monoamine Oxidase A	Protein Coding	21.96	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15670397
4	PTK7	Protein Tyrosine Kinase 7 (Inactive)	Protein Coding	20.59	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	8771610
5	GRPR	Gastrin Releasing Peptide Receptor	Protein Coding	20.32	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	STMN1	Stathmin 1	Protein Coding	20	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CCKBR	Cholecystokinin B Receptor	Protein Coding	19.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	7786960
8	SLC6A2	Solute Carrier Family 6 Member 2	Protein Coding	17.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15722184
9	PIR	Pirin	Protein Coding	16.66	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	OPRK1	Opioid Receptor Kappa 1	Protein Coding	16.26	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	RGS2	Regulator Of G Protein Signaling 2	Protein Coding	15.91	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Agoraphobia

Sources

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Sources

Pathways for Agoraphobia

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.65	HTR1A MAOA SLC6A4
2	Serotonergic synapse ³⁷	11.38	HTR1A MAOA SLC6A4
3	Monoamine Transport ¹ Show member pathways Serotonin Transporter Activity ¹	10.77	MAOA SLC6A2 SLC6A4
4	Neurotransmitter Clearance In The Synaptic Cleft ⁶⁶ Show member pathways Dopamine clearance from the synaptic cleft ⁶⁶ Enzymatic degradation of dopamine by COMT ⁶⁶ Enzymatic degradation of Dopamine by monoamine oxidase ⁶⁶ melatonin degradation II ¹ Metabolism of serotonin ⁶⁶ Serotonin clearance from the synaptic cleft ⁶⁶	10.74	MAOA SLC6A4
5	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶¹	10.25	HTR1A MAOA SLC6A4

Sources

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.86	CCKBR GRPR HTR1A OPRK1 PTK7 RGS2
2	membrane	GO:0016020	9.85	CCKBR GRPR HTR1A MAOA OPRK1 PTK7
3	integral component of plasma membrane	GO:0005887	9.43	GRPR HTR1A OPRK1 PTK7 SLC6A2 SLC6A4
4	neuron projection	GO:0043005	9.02	OPRK1 RGS2 SLC6A2 SLC6A4 STMN1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	9.85	CCKBR GRPR HTR1A OPRK1 PTK7 STMN1
2	chemical synaptic transmission	GO:0007268	9.61	HTR1A OPRK1 SLC6A2
3	social behavior	GO:0035176	9.46	GRPR SLC6A4
4	neurotransmitter transport	GO:0006836	9.4	SLC6A2 SLC6A4
5	vasoconstriction	GO:0042310	9.32	HTR1A SLC6A4
6	monoamine transport	GO:0015844	9.26	SLC6A2 SLC6A4
7	behavior	GO:0007610	9.16	HTR1A OPRK1
8	phospholipase C-activating G-protein coupled receptor signaling pathway	GO:0007200	9.13	CCKBR GRPR OPRK1
9	dopamine uptake involved in synaptic transmission	GO:0051583	8.62	SLC6A2 SLC6A4

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	beta-tubulin binding	GO:0048487	9.32	RGS2 SLC6A2
2	neuropeptide binding	GO:0042923	9.26	GRPR OPRK1
3	neurotransmitter:sodium symporter activity	GO:0005328	9.16	SLC6A2 SLC6A4
4	monoamine transmembrane transporter activity	GO:0008504	8.96	SLC6A2 SLC6A4
5	dopamine:sodium symporter activity	GO:0005330	8.62	SLC6A2 SLC6A4

Sources

Sources for Agoraphobia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Agoraphobia

Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Classifications:

External Ids:

Summaries for Agoraphobia

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Agoraphobia:

Symptoms & Phenotypes for Agoraphobia

MGI Mouse Phenotypes related to Agoraphobia:

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

Publications for Agoraphobia

Articles related to Agoraphobia:

Genes for Agoraphobia

Genes related to Agoraphobia (0 elite genes):

Variations for Agoraphobia

Expression for Agoraphobia

Pathways for Agoraphobia

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

Sources for Agoraphobia

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :